We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Human Peptide Database Project Will Facilitate Proteome Research

By LabMedica International staff writers
Posted on 08 Jun 2010
A major project is underway to amass a database that will allow researchers with access to a mass spectrometer to analyze almost any of the estimated 25,000 proteins encoded by the human genome.

The project, known as the Human Proteome MRMAtlas is being conducted by the nonprofit Institute for Systems Biology (Seattle, WA, USA) in collaboration with the major manufacturer of laboratory equipment Thermo Fisher Scientific Inc. More...
(Milford, MA, USA).

During the two years that the project will be running, Thermo Fisher will provide researchers at the Institute for Systems Biology with up to 100,000 synthetic peptides. The investigators will use the synthetic peptides and mass spectrometry to identify and document at least four proteotypic, or unique, peptides for each human protein. In addition, the investigators will use thousands of custom Thermo Scientific HeavyPeptide AQUA standards to measure the abundance of the natural peptides and develop precise quantitative MRM/SRM assays.

The accumulated data will be published as a database available to researchers around the world.

"The time is right to create the complete human proteome MRMAtlas,” said Dr. Robert Moritz, associate professor and proteomics director at the Institute for Systems Biology. "This will undoubtedly accelerate efforts to develop sensitive and reliable assays for early detection, therapy assessment, and prognosis evaluation for cancer as well as other human diseases. It will pave a path to personalized medicine by improving the development of individually tailored therapies.”

"By reducing the time, effort, and cost to perform these assays, the database will dramatically increase the research output in biomarker discovery, confirmation, and validation,” said Joel Louette, commercial director for at Thermo Fisher. "We are proud to play a role in this project, which will speed up and decrease costs associated with drug development, boost personalized medicine, and support human health monitoring.”

Related Links:
Institute for Systems Biology
Thermo Fisher Scientific Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.